NCT03236844View on ClinicalTrials.gov

Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

114

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

December 15, 2017

Study Completion Date

December 15, 2017

Conditions

Healthy Participants

Interventions

DRUG

Gantenerumab

Gantenerumab HCLF manufactured by either G3 or G4 process will be administered on Day 1 (in the abdomen).

Trial Locations (3)

66219

PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa

84106

PRA Health Sciences, Salt Lake City

08053

PRA, Marlton

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT03236844 - Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants | Biotech Hunter | Biotech Hunter